<VariationArchive VariationID="2816521" VariationName="NM_001134407.3(GRIN2A):c.2023_2027del (p.Asp675fs)" VariationType="Deletion" Accession="VCV002816521" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-29" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2984024" VariationID="2816521">
      <GeneList>
        <Gene Symbol="GRIN2A" FullName="glutamate ionotropic receptor NMDA type subunit 2A" GeneID="2903" HGNC_ID="HGNC:4585" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="9753404" stop="10182908" display_start="9753404" display_stop="10182908" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="9847264" stop="10276610" display_start="9847264" display_stop="10276610" Strand="-" />
          </Location>
          <OMIM>138253</OMIM>
          <Haploinsufficiency last_evaluated="2022-04-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GRIN2A">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-04-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GRIN2A">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_001134407.3(GRIN2A):c.2023_2027del (p.Asp675fs)</Name>
      <CanonicalSPDI>NC_000016.10:9822404:TAGTC:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="9822405" stop="9822409" display_start="9822405" display_stop="9822409" variantLength="5" positionVCF="9822404" referenceAlleleVCF="ATAGTC" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="9916262" stop="9916266" display_start="9916262" display_stop="9916266" variantLength="5" positionVCF="9916261" referenceAlleleVCF="ATAGTC" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>D675fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.9822405_9822409del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.9822405_9822409del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001134407.3" sequenceAccession="NM_001134407" sequenceVersion="3" change="c.2023_2027del" MANESelect="true">
            <Expression>NM_001134407.3:c.2023_2027del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001127879.1" sequenceAccession="NP_001127879" sequenceVersion="1" change="p.Asp675fs">
            <Expression>NP_001127879.1:p.Asp675fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001134408.2" sequenceAccession="NM_001134408" sequenceVersion="2" change="c.2023_2027del">
            <Expression>NM_001134408.2:c.2023_2027del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001127880.1" sequenceAccession="NP_001127880" sequenceVersion="1" change="p.Asp675fs">
            <Expression>NP_001127880.1:p.Asp675fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.9916262_9916266del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.9916262_9916266del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011812.2" sequenceAccession="NG_011812" sequenceVersion="2" change="g.365346_365350del">
            <Expression>NG_011812.2:g.365346_365350del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000833.5" sequenceAccession="NM_000833" sequenceVersion="5" change="c.2023_2027del">
            <Expression>NM_000833.5:c.2023_2027del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000824.1" sequenceAccession="NP_000824" sequenceVersion="1" change="p.Asp675fs">
            <Expression>NP_000824.1:p.Asp675fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001134407.3(GRIN2A):c.2023_2027del (p.Asp675fs) AND Landau-Kleffner syndrome" Accession="RCV003741789" Version="1">
        <ClassifiedConditionList TraitSetID="12189">
          <ClassifiedCondition DB="MedGen" ID="C0282512">Landau-Kleffner syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-12-02" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2024-02-20" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">23933819</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23933820</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="12189" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5374" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">EPILEPSY, FOCAL, WITH SPEECH DISORDER AND WITH OR WITHOUT IMPAIRED INTELLECTUAL DEVELOPMENT</ElementValue>
                <XRef Type="MIM" ID="245570" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">APHASIA, ACQUIRED, WITH EPILEPSY</ElementValue>
                <XRef Type="MIM" ID="245570" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Epilepsy with neurodevelopmental defects</ElementValue>
                <XRef ID="Epilepsy+with+neurodevelopmental+defects/8322" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Landau-Kleffner syndrome</ElementValue>
                <XRef ID="Landau-Kleffner+syndrome/4080" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009509" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acquired aphasia with convulsive disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acquired epileptiform aphasia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ADRESD</ElementValue>
                <XRef ID="245570" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RESDAD</ElementValue>
                <XRef ID="245570" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">FESD</ElementValue>
                <XRef Type="MIM" ID="245570" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">LKS</ElementValue>
                <XRef ID="245570" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">GRIN2A-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6855" />
                <XRef ID="6855" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GRIN2A-Related Speech Disorders and Epilepsy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GRIN2A-related speech disorders and epilepsy are characterized by speech disorders in all affected individuals and a range of epilepsy syndromes present in about 90%. Severe speech disorders observed can include dysarthria and speech dyspraxia, and both receptive and expressive language delay/regression; more mildly affected individuals may display subtly impaired intelligibility of conversational speech. Epilepsy features include seizure onset usually between ages three and six years, focal epilepsy with language and/or global developmental regression, and electroencephalogram (EEG) showing continuous spike-and-wave discharges in sleep or very active centrotemporal discharges. Seizure types include seizures associated with aura of perioral paresthesia, focal or focal motor seizures (often evolving to generalized tonic-clonic), and atypical absence seizures. Epilepsy syndromes can include: Landau-Kleffner syndrome (LKS), epileptic encephalopathy with continuous spike-and-wave during sleep (ECSWS), childhood epilepsy with centrotemporal spikes (CECTS), atypical childhood epilepsy with centrotemporal spikes (ACECTS), autosomal dominant rolandic epilepsy with speech dyspraxia (ADRESD), and infantile-onset epileptic encephalopathy.</Attribute>
                <XRef ID="NBK385627" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">GRIN2A-Related Encephalopathy with Epilepsy</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">27683935</ID>
                <ID Source="BookShelf">NBK385627</ID>
              </Citation>
              <XRef ID="1945" DB="Orphanet" />
              <XRef ID="725" DB="Orphanet" />
              <XRef ID="98818" DB="Orphanet" />
              <XRef ID="C0282512" DB="MedGen" />
              <XRef ID="MONDO:0009509" DB="MONDO" />
              <XRef Type="MIM" ID="245570" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8280062" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="17957478|MedGen:C1832814" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004485554" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23933819</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23933820</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Asp675Phefs*11) in the GRIN2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GRIN2A are known to be pathogenic (PMID: 23933819, 23933820). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with GRIN2A-related conditions. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GRIN2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.9916262_9916266del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1832814" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8280062" TraitType="Disease" MappingType="XRef" MappingValue="C1832814" MappingRef="MedGen">
        <MedGen CUI="C0282512" Name="Landau-Kleffner syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

